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Background: Obesity has been linked to metabolic syndrome (MS), which increases the risk of cardiovascular
disease (CVD). Polymorphisms of Apolipoprotein E have also been associated with increased CVD risk.
Therefore, this study investigated the association between MS and Apo E polymorphisms.
Methods:Wemeasured anthropometric and biochemical variables and determined the Apo E genotype of 147
grade III obese patients.
Results: The percentage of female subjects was 86.4%. Themean age and BMI of the subjects were 41 years and
53.5 kg/m2, respectively. MS had been diagnosed in 79% of the subjects. The proportions of those exhibiting
MS risk factors were as follows: 100% had a high BMI, 80% had hypertension, 65% had low levels of high-
density lipoprotein (HDL), 38% had diabetes, and 39% had hypertriglyceridemia. We found ﬁve genotypes for
which the allelic distribution was different in the MS group compared to the general population. The ε4 allele
was more frequent in the group with neither MS nor hypertension.
Conclusions: Themorbidly obese patients exhibited a higher incidence of MS and a different allelic distribution
when compared with other populations. The ε4 allele was associated with the absence of MS and
hypertension.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Obesity, which is characterized by excess body fat, is a public
health problem [1,2]. The degree of obesity can be deﬁned by the body
mass index (BMI), which is calculated by dividing an individual's
weight in kilograms by the square of his or her height inmeters. A BMI
above 30 kg/m2 is considered grade I obesity, and one above 40 kg/m2
is grade III obesity [3]. The accumulation of visceral fat is the main
cause of the deleterious effects of obesity [4]. Visceral fat is associated
with the production and secretion of inﬂammatory adipokines, such
as IL-6 and TNF-α, which lead to insulin resistance, dyslipidemia, and
hypertension [4]. These complications are components of the
metabolic syndrome (MetS) [5]. The metabolic syndrome is deﬁned
by the American Heart Association (AHA) as the presence of at least
three of the following symptoms: increased waist circumference,
hypertension, hypertriglyceridemia, a low level of high-densityf Minas Gerais (UFMG), Belo
ica e Imunologia, Instituto de
970 Belo Horizonte/MG, Brazil.
lvarez-Leite).
vier OA license.lipoprotein cholesterol (HDL-C); and impaired glucose tolerance,
including diabetes mellitus (DM) [6]. Thus, extremely obese subjects
often present with MetS, DM, hypertension, or hyperlipidemia [7].
Some of the components of MetS may be inﬂuenced by
environmental or genetic factors. Apolipoprotein E (Apo E) is an
apoprotein that is found in all lipoproteins except low-density
lipoprotein (LDL); its isoforms inﬂuence the levels of both tri-
glycerides (TG) and circulating cholesterol and the risk of coronary
artery disease, which is a major complication of MetS. Besides its role
in lipid metabolism, Apo E and its isoforms are involved in the
development of Alzheimer's disease and possess antioxidant and anti-
inﬂammatory properties [8].
The Apo E gene has the ε2, ε3, and ε4 alleles, which can lead to six
different genotypes in combination [9–11]. The ε3 allele is the most
common; it is present in more than 80% of individuals [12]. The other
alleles probably originated from mutations in the ε3 allele. The three
isoforms differ in their amino acid sequence at positions 112 and 158.
Apo E3 contains a cysteine at position 112 and an arginine at position
158. Apo E2 has a cysteine at both positions, and Apo E4 has an
arginine at both positions [6]. The ε2 allele is associated with lower
levels of LDL, decreased clearance of intermediate-density lipoprotein
(IDL) by the liver, and a lower incidence of cardiovascular disease [13].
By contrast, the ε4 allele is associated with elevated LDL cholesterol,
Table 1
Frequency of risk factors associated withMS and Apo E alleles in severely obese subjects
by sex.
Variables Women (n=122) Men (n=25) P-value
BMI (kg/m2) 52.5 (48.6–57.8) 55.4 (53.4–64.5) b0.05*
Glucose (mg/dL) 93.5 (82–109) 93.5 (90–123) 0.45
HDL (mg/dL) 44 (39–54) 42 (32–50) 0.12
TG (mg/dL) 133.5 (102–177) 145 (104–185) 0.58
Blood Pressure (mm Hg)
Systolic 130 (110–150) 150 (140–160) 0.13
Diastolic 80 (70–90) 100 (90–100) 0.08
Allele ε2 (%) 9.0 18.0 0.07
Allele ε3 (%) 82.8 72.0 0.11
Allele ε4 (%) 8.2 10.0 0.59
Presence of MS (%) 77 88 0.28
The values above are the medians (interquartile range); signiﬁcance was determined
using the Mann–Whitney U test. * Statistically signiﬁcant difference. Those individuals
who used drugs to treat comorbidities listed above were excluded.
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and Alzheimer's disease [14]. The antagonistic effects of the ε2 and ε4
alleles on lipoprotein levels is possibly related to the absorption,
removal, conversion, and regulation of lipoproteins [8].
The link between Apo E polymorphisms and obesity and MetS has
been investigated [15–17]. Obesity and abdominal fat accumulation
are associated with increased plasma very low density lipoprotein —
VLDL, and the ε2 allele increases this lipoprotein [18].
Endogenous Apo E is also an important modulator of lipid
metabolism in adipocytes, and the ε2 allele is able to increase the
synthesis of TG and free fatty acids along with the expression of genes
involved in TG metabolism and oxidation in adipocytes [15]. The
inﬂuence of Apo E in adiposity was experimentally conﬁrmed using
Apo E knockout mice, which had smaller adipocytes and were more
resistant to the induction of obesity compared to control animals [19].
Studying the link between Apo E polymorphisms and extreme obesity
may allow clinicians to identify patients who would beneﬁt from the
early treatment of severe obesity.
This study the ﬁrst of its kind aimed to investigate the inﬂuence of
Apo E polymorphisms on severe obesity and the metabolic syndrome.
2. Materials and methods
A total of 147 subjects with severe obesity who underwent
outpatient treatment at the Borges da Costa, Clinical Hospital,
Universidade Federal de Minas Gerais (Brazil) from August 2006 to
April 2010 were evaluated. This study was approved by the Ethics
Committee on Human Research of Universidade Federal de Minas
Gerais, Opinion No. ETIC 092/06.
Weight was determined using a scale with a 300-kg capacity and a
100-g precision (Welmy®). Blood pressure was measured using a
sphygmomanometer suitable for obese subjects. Medication use,Table 2
Clinical characteristics of the obese subjects.
Variables All subjects (n=147) Without metabolic s
% Women (n/total) 83 (122/147) 90.3% (28/31)
Age (years) 41 (34–49) 41 (29–48)
BMI (kg/m2) 53.5 (48.7–58.8) 51.9 (45.7–58.2)
Glucose (mg/dL) 93.5 (84.5–112.5) 90.5 (80–95)
Total cholesterol (mg/dL) 188 (164–210) 183 (162.5–198)
LDL (mg/dL) 112 (95–133) 104 (83.5–123.5)
HDL (mg/dL) 44 (37–53) 52 (48.5–57)
TG (mg/dL) 135 (104–177) 112.5 (86.5–127.5)
Blood pressure (mm Hg)
Diastolic 85 (80–90) 80 (80–90)
Systolic 130 (120–150) 120 (120–150)
The values presented above are the medians (interquartile range); signiﬁcance was det
individuals who used drugs to treat comorbidities listed above were excluded.comorbidities, and height were recorded. Serum total cholesterol, TG,
HDL-C, and glucose were also measured [20]. Subjects were separated
into two groups based on the presence of absence of MetS. For the
diagnosis of MetS, we adapted the AHA criteria by replacing waist
circumference with body mass index, as previously described [21,22].
We used this adaptation because of the difﬁculty of measuring waist
circumference in severely obese subjects.
To determine the Apo E genotype, buccal swab samples were
collected. DNA was extracted using a kit (Sigma Aldrich®, USA).
Polymorphic segments of the Apo E gene were evaluated by PCR-RFLP
[23]. Subjects with the ε2ε4 genotype were excluded from the
analysis of biochemical variables because these alleles exert opposing
effects.
Statistical analysis was performed using Stata version 9.1. We used
the chi-square test to compare the allele frequencies and genotype.
The Student's t-test was used to compare the means of the parametric
data, and the Mann–Whitney U test was used for the nonparametric
data. A P-value of less than or equal to 0.05 was considered
statistically signiﬁcant.
3. Results
Most of the patients were women (83%). The mean age was
41 years (34–49), and the mean BMI was 48.7 kg/m2 (maximum
58.8 kg/m2). All of the subjects presented grade III obesity. With the
exception of weight, there were no differences between the sexes for
the variables measured (Table 1). Therefore, all the subjects were
analyzed together. Of the 147 subjects, 116 subjects (78.9%) presented
with MetS (Table 2). Fasting glucose, HDL-C, and TG were higher in
the MetS group compared to the non-MetS group. Total cholesterol,
LDL, blood pressure, and BMI were similar between the two groups
(Table 2).
Among the MetS variables in all of the subjects, increased waist
circumference was the most prevalent (100%) followed by hyperten-
sion (80%) and low HDL-C (65%) (Table 3). DM and hypertriglycer-
idemia were present in less than 40% of the subjects. However, DM
and hypertriglyceridemia were present in only one patient without
MetS, whereas almost 50% of the subjects with MetS presented these
conditions (Table 3). The non-MetS variables (e.g., sex, age, total
cholesterol, and LDL) were similar between the subjects with or
without MetS. Although they are also determinants of MetS, the
systolic and diastolic blood pressures were not different between the
two groups.
Both groups exhibited Hardy–Weinberg equilibrium for allelic
distribution. The allelic distribution of the ε2, ε3, and ε4 alleles was
10.5%, 80.9%, and 8.5%, respectively. We observed ﬁve (ε2ε3, ε2ε4,
ε3ε3, ε3ε4, and ε4ε4) of the six possible genotypes. The frequency of
the ε2 and ε3 alleles was not different between the two groups
(p=0.34, OR 1.705, CI 0.569–5.106). However, the ε4 allele was more
frequent in individuals without MetS (p=0.027, OR=0.37, CI 0.16–yndrome (n=31) With metabolic syndrome (n=116) P-value
81% (94/116) 0.28
41 (34–49) 0.32
53.6 (48.7–58.7) 0.40
98 (86–120) b0.05*
188 (165–214) 0.51
113 (97–134) 0.15
42 (36–49) b0.05*
146 (113–189) b0.05*
90 (80–90) 0.43
130 (120–150) 0.44
ermined using the Mann–Whitney U test. * Statistically signiﬁcant difference. Those
Table 3
Prevalence of components of metabolic syndrome on class III obese subjects.
Components Without
metabolic
syndrome
(n=31)
With
metabolic
syndrome
(n=116)
All subjects
(n=147)
P-value
Hypertension 61.3% (19) 85.3% (99) 80.2% (118) b0.005
Hypertriglyceridemia 3.2% (1) 49.1% (57) 39.5% (58) b0.001
Diabetes mellitus 3.2% (1) 47.4% (55) 38.1% (56) b0.001
Low HDL 19.4% (6) 74.1% (86) 65.2% (92) b0.001
Signiﬁcance was determined using Fisher's exact test. We considered the following
reference values for each parameter: hypertension (blood pressure) N130/90 mm Hg,
hypertriglyceridemia (TG) N150 mg/dL, diabetes mellitus (blood glucose) N126 mg/dl,
low HDL in men b40 mg/dL, and low HDL in women b50 mg/dL.
Table 5
Changes in metabolic syndrome variables (%) by alleles in class III obese subjects with
and without metabolic syndrome.
Without metabolic syndrome With metabolic syndrome
ε2
(n=4)
ε3
(n=40)
ε4
(n=14)
ε2
(n=46)
ε3
(n=158)
ε4
(n=20)
Hyperglycemia 0 5.0 0 39.15 49.4 50.0
Hypertriglyceridemia 0 5.0 0 52.17 49.4 40.0
Low HDL 0 25.0 0 73.9 73.4 90.0
Hypertension 100.0 50.0 85.7 91.3 93.7 90.0⁎
Signiﬁcance was determined using Fisher's exact test. * Statistically different from
group ε3 with MS. We considered the following reference values for each parameter:
hypertension (blood pressure) N130/90 mm Hg, hypertriglyceridemia (TG) N150 mg/
dL, diabetes mellitus (blood glucose) N126 mg/dl, low HDL for men b40 mg/dL, and low
HDL for women b50 mg/dL.
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the subjects without MetS compared to those withMetS. Additionally,
in subjects with MetS, the frequency of the ε3ε4 and ε4ε4 genotypes
was signiﬁcantly lower than the ε2ε3 genotype (Table 4).
We then analyzed the inﬂuence of the Apo E alleles and genotypes
on MetS variables (Table 5). Hypertension was less prevalent in the
subjects with the ε4 allele compared to those with the ε3 allele. Other
factors associated with MetS had a similar distribution between both
alleles. Comparing genotypes, there were no signiﬁcant differences
between the groups, except that subjects with the ε3ε4 or ε4ε4
genotypes had lower TG levels compared to subjects with the ε3ε3
genotype (data not shown). Although this study found that only 21%
of the subjects did not have MetS, the absence of MetS was observed
in 44% of the subjects with the ε4 allele (Table 5). However, among the
subjects with only the ε2 allele, 16.1% did not have MetS. After
multivariate analysis using logistic regression, the presence of MetS
was found to be signiﬁcantly associated with TG levels (Pb0.05, OR
1.00), impaired glucose tolerance (Pb0.05, OR 1.03), HDL (Pb0.05, OR
0.921), and blood pressure. The presence of the ε4 allele was
negatively associated with MetS (P=0.04, OR 0.310) (Table 6).
4. Discussion
This is the ﬁrst work to study Apo E polymorphisms in subjects
with extreme obesity. These results indicate that the isoforms are
related not only to extreme obesity but also to the presence or
absence of MetS. Most of the subjects in this study were women
(n=122), which is consistent with results from the literature because
women (due to biological, environmental, and cultural factors as well
as hormonal changes during pregnancy and menopause) are more
susceptible to obesity [24,25]. However, when the male and femaleTable 4
Distribution and frequency of alleles and genotypes of Apo E in class III obese subjects
with and without metabolic syndrome (MetS).
All subjects Without MetS With MetS P-value
Allele
ε2 10.5% (31) 6.5% (4) 11.6% (27) 0.238
ε3 80.9% (238) 77.4% (48) 81.9% (190) 0.607
ε4 8.5% (25) 16.1% (10)* 6.5% (15) 0.040
Total 294 62 232
Genotype
ε2ε3 17% (25) 6.5%(2) 19.8% (23) 0.078
ε2ε4 4% (6) 6.5% (2) 3.5% (4) 0.607
ε3ε3 67.4% (99) 64.5% (20) 68% (79) 0.705
ε3ε4+ε4ε4 11.6% (17) 22.6% (7)** 8.7% (10) 0.052
Total 147 31 116
The values are expressed as the percentage of subjects (%). Signiﬁcance was determined
using Fisher's exact test to check the distribution of alleles and genotypes. * Statistically
more frequent in subjects without MS compared to MS subjects (p=0.040). The
genotype e3/4+e4/4 is less frequent than e2/3 in subjects with MS. ** More frequent in
subjects without MS compared to MS subjects.subjects were analyzed separately, only the BMI was higher in men;
the other factors, including the allelic distribution, were similar
between the sexes. Because the groupwas homogeneous, the analyses
were performed by including men and women in the same group.
The 78.9% MetS prevalence observed here is similar to that
described previously for severely obese subjects [7]. Fasting glucose,
HDL-C, and TG, which are factors related to the diagnosis of MetS,
were signiﬁcantly higher in theMetS subjects. BMI, which was used in
place of waist circumference, and blood pressure were similar
between the groups, even after excluding those who used medica-
tions. These results suggest that blood glucose, HDL-C, and TG may be
better markers to distinguish between subjects with MetS and
healthy, obese subjects. Moreover, LDL level, an important element
of ischemic disease, was not associated with MetS.
Approximately 21% of the subjects did not have MetS. However,
these subjects presented comorbidities related to the syndrome, such
as hypertension (61.3%), dyslipidemia (22.6%), and DM (19.4%).
The Apo E allelic distribution in this study is similar to the
distribution observed in other countries. The ε3 allele is the most
prevalent, followed by the ε4 and ε2 alleles [26,27]. This distribution
was also observed in a study that examined 72 obese subjects; the ε4
allele had a prevalence of 13.1% [28].
In our study, there was a slight reversal of this distribution. The
frequency of the ε2 allele was slightly higher than that of the ε4 allele.
Among the subjects without MetS, the ε4 allele appeared more
frequently. At the same way, phenotypes containing ε4 allele (ε4ε4
and ε3ε4) strongly tended (p=0.052) to be more frequent in the
subjects without metabolic syndrome. These data suggest that the ε4
allele is associated with fewer complications of obesity. In a study of
animals with diet-induced obesity and either the Apo E ε3ε3 or ε4ε4
genotype, the subjects with ε4ε4 had less weight gain and visceral fat
compared to ε3ε3 animals [29]. However, ε4ε4 animals had impaired
glucose sensitivity and increased adipocyte levels. Thus, we suggest
that in a population with extreme levels of obesity, the glucose
intolerance observed with the ε4 allele is less relevant than the
lipotoxicity and increased TG observed in this obese population.
The protective effect of the ε2 allele in atherosclerosis is typically
associated with low concentrations of LDL [13]. However, a homozygousTable 6
Multivariate logistic regression for metabolic syndrome in class III obese subjects.
Odds ratio P-value Conﬁdence interval
TG 1.007 0.00 1.001–1.014
Glucose 1.030 0.00 1.011–1.050
HDL 0.921 0.00 0.891–0.952
Hypertension 2.638 0.01 1.212–5.743
Allele ε2 3.980 0.11 0.738–21.46
Allele ε4 0.310 0.04 0.102–0.940
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to its lower afﬁnity for the E receptor [30]. It is possible that even the
heterozygous ε2 genotype could trigger hypertriglyceridemia, an impor-
tant factor in MetS. It is known that excess circulating fatty acids trigger
several of the changesobserved inMetS, suchas reduced levels ofHDLand
hypertension. Although not signiﬁcant, we showed that in patients with
MetS, low HDL was detected in 90% of ε4 individuals compared to 73% of
ε3subjects.On theotherhand,hypertriglyceridemiawaspresent in45%of
ε2 carriers and was observed in only 28% of the ε4 carriers. It is unlikely
that our results reﬂect just a random association between ε4 and low
prevalence of MetS, since other characteristics of MetS and lipid
metabolism seen for both and ε2 and ε4 alleles are in agreement to data
previously published [11,29,31].
The relationship between the alleles and glucose intolerance is
unclear. Some studies have shown an association between the ε4 allele
and insulin resistance and hyperglycemia, especially among men [32].
However, a more recent study found no association between abnormal
glucose homeostasis and the ε4 allele [11]. A study examining theeffects
of the Apo E alleles on obesity and diabetes in 465 subjects with
Alzheimer's disease indicated that diabetes and obesity were less
common in those with the ε4 allele [31].
It would be expected that the protective effect of the ε4 allele
relative to ε2 involves lipidmetabolism because individuals who carry
the ε4 allele remove circulating triglycerides more effectively [8].
However, our results indicate that the ε4 allele does not affect TG
levels.
The relationship between the ε4 allele and hypertension is not
well established, as indicated by the conﬂicting data [33]. Our study is
consistent with a study by Cho et al. [29], which indicated that the ε4
allele was related to lower blood pressure in obese and overweight
subjects compared to other alleles. As in our study, the other
parameters involved in MetS, such as low HDL, TG, and waist
circumference, were not different between the alleles.
In conclusion, Apo E polymorphisms have a different distribution
in extremely obese subjects as compared with the general population,
and the ε2 allele is more common than is the ε4 allele in obese
subjects. The ε4 allele was associated with a lower frequency of MetS
and hypertension.
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